Crinetics Pharmaceuticals, Inc.
CRNX
株式のランク
#2239
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
株価
$84.95
最終同期: 2026-09-01
時価総額
$9.00B
変化（1日）
0.00%
変化（1年）
98.25%
国
US
取引 Crinetics Pharmaceuticals, Inc. (CRNX)
カテゴリー
Healthcare
Crinetics Pharmaceuticals, Inc.（CRNX）のP/B比率
October 2026 時点のP/B比率 TTM: 7.52
Crinetics Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 7.52 です。2023 年末時点でのP/B比率は 3.83 でした。
Crinetics Pharmaceuticals, Inc. の P/B 比率の履歴（2016 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 7.52 | 141.13% |
| 2024 | 3.12 | -18.65% |
| 2023 | 3.83 | 27.45% |
| 2022 | 3.01 | -8.58% |
| 2021 | 3.29 | 29.34% |
| 2020 | 2.54 | -139.33% |
| 2019 | -6.47 | -22.97% |
| 2018 | -8.39 | -62.93% |
| 2017 | -22.64 | -58.70% |
| 2016 | -54.83 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -16.91% |
US
|
|
| 13.2547 | 76.18% |
US
|
|
| 4.208 | -44.07% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -17.82% |
NL
|
